QTTB Q32 Bio | $18.19
-5.8% | 5/21/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | Low | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $0.74
-2.6% | 5/14/2024 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/14/2024 |
EHAB Enhabit | $8.68
-1.8% | 5/14/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong Sell -> Hold | | Low | View details for Leerink Partnrs rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AIRS AirSculpt Technologies | $4.01
+0.5% | 5/14/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
AQST Aquestive Therapeutics | $2.68
-1.8% | 5/10/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Strong-Buy | | Low | View details for Leerink Partnrs rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $23.90
-0.5% | 5/8/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
|
BPMC Blueprint Medicines | $106.71
+2.7% | 5/6/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Underperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $61.02
-0.1% | 5/1/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 5/1/2024 |
XOMA XOMA | $22.31
-7.8% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of XOMA (NASDAQ:XOMA) on 4/29/2024 |
LXRX Lexicon Pharmaceuticals | $1.75
+1.7% | 4/30/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
IMCR Immunocore | $35.94
-2.8% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
NGNE Neurogene | $30.32
-24.2% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
DCPH Deciphera Pharmaceuticals | $25.59
| 4/29/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 4/29/2024 |
TNDM Tandem Diabetes Care | $42.83
-0.4% | 4/25/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
CVAC CureVac | $3.25
-6.6% | 4/25/2024 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
RNAC Cartesian Therapeutics | $21.76
-6.7% | 4/23/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $22.89
-2.1% | 4/16/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $7.32
-2.1% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst R. Li | Outperform | | Low | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $18.32
-0.7% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ALPN Alpine Immune Sciences | $64.97
| 4/11/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Alpine Immune Sciences (NASDAQ:ALPN) on 4/11/2024 |
SWAV Shockwave Medical | $334.75
| 4/5/2024 | Downgraded by | Leerink Partnrs | Analyst M. Kratky | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Shockwave Medical (NASDAQ:SWAV) on 4/5/2024 |
ARDX Ardelyx | $5.95
-5.4% | 4/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $7.87
-1.5% | 4/3/2024 | Reiterated by | Leerink Partnrs | Analyst J. Park | Outperform | | Low | View details for Leerink Partnrs rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $78.10
+1.2% | 4/1/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $3.95
-6.4% | 3/25/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
FUSN Fusion Pharmaceuticals | $21.55
| 3/19/2024 | Downgraded by | Leerink Partnrs | Analyst F. Khurshid | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
RGLS Regulus Therapeutics | $2.48
+4.6% | 3/18/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.63
-3.1% | 3/14/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $1.62
-1.8% | 3/11/2024 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $12.21
+4.9% | 3/6/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $8.08
-3.9% | 3/5/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $7.44
-5.7% | 3/4/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
IDYA IDEAYA Biosciences | $37.27
-0.8% | 2/23/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 2/23/2024 |
DOCS Doximity | $27.56
-1.9% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $13.37
-7.0% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Certara (NASDAQ:CERT) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $25.66
| 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RLAY Relay Therapeutics | $7.03
-0.8% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 2/22/2024 |
PGNY Progyny | $25.73
-3.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
NVST Envista | $16.99
-1.3% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Underperform | | Low | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 2/26/2024 |
NUVL Nuvalent | $78.10
+1.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 2/22/2024 |
This Weight Loss Company Can't Make Enough Product (Ad) A tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel.
They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December! Get the name of the company and their stock ticker here >>> |
LH Laboratory Co. of America | $206.49
+2.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
DGX Quest Diagnostics | $137.32
+0.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
COGT Cogent Biosciences | $8.50
-3.4% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Cogent Biosciences (NASDAQ:COGT) on 2/22/2024 |
ARVN Arvinas | $24.82
-0.5% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Arvinas (NASDAQ:ARVN) on 2/22/2024 |
ALGN Align Technology | $242.20
-1.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $6.15
-0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
WBA Walgreens Boots Alliance | $16.11
+6.3% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
TDOC Teladoc Health | $10.10
-0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
RCM R1 RCM | $12.52
+0.3% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of R1 RCM (NASDAQ:RCM) on 2/26/2024 |
PINC Premier | $18.18
+0.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Market Perform | | Low | View details for Leerink Partnrs rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $25.38
+11.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $17.09
+0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $602.93
+0.9% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of McKesson (NYSE:MCK) on 2/26/2024 |
IQV IQVIA | $212.93
-0.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HSIC Henry Schein | $68.28
+3.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
HIMS Hims & Hers Health | $24.76
+2.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $8.16
-2.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
CVS CVS Health | $61.02
-0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 2/26/2024 |
COR Cencora | $237.22
+1.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $104.09
+3.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
APLT Applied Therapeutics | $4.50
-6.8% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $3.19
-3.6% | 2/21/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
ENGN enGene | $8.36
-3.4% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
BTSG BrightSpring Health Services | $10.52
+1.2% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst W. Mayo | Outperform | | Low | View details for Leerink Partnrs rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
SYBX Synlogic | $1.59
| 2/9/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $305.99
+0.9% | 2/7/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $306.04
+3.0% | 2/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $3.89
-4.7% | 1/31/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $6.50
| 1/30/2024 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $13.28
+1.0% | 1/29/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $3.42
-6.6% | 1/23/2024 | Reiterated by | Leerink Partnrs | Analyst J. La. Rosa | Outperform | | Low | View details for Leerink Partnrs rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL agilon health | $6.74
+1.4% | 1/8/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $0.74
+1.4% | 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $5.71
-4.7% | 12/19/2023 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
NBTX Nanobiotix | $4.54
-6.0% | 12/8/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TRML Tourmaline Bio | $15.55
+3.4% | 12/7/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Tourmaline Bio (NASDAQ:TRML) on 12/7/2023 |
MOR MorphoSys | $18.12
-1.0% | 12/6/2023 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of MorphoSys (NASDAQ:MOR) on 12/6/2023 |
TNYA Tenaya Therapeutics | $3.16
-4.2% | 11/30/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $15.64
-3.8% | 11/28/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $13.55
| 11/14/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ACRS Aclaris Therapeutics | $1.13
| 11/13/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/13/2023 |
ZNTL Zentalis Pharmaceuticals | $4.14
-50.7% | 11/7/2023 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $3.89
-4.7% | 10/30/2023 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $23.17
-3.6% | 10/20/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
OLK Olink Holding AB (publ) | $25.50
-0.2% | 10/17/2023 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Olink Holding AB (publ) (NASDAQ:OLK) on 10/17/2023 |
FDMT 4D Molecular Therapeutics | $22.78
-4.3% | 10/18/2023 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
PLRX Pliant Therapeutics | $10.71
-4.4% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 10/16/2023 |
MORF Morphic | $26.16
+0.2% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Morphic (NASDAQ:MORF) on 10/16/2023 |
KYMR Kymera Therapeutics | $31.20
-1.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Market Perform | | Low | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/16/2023 |
VCEL Vericel | $43.37
+4.0% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
This Weight Loss Company Can't Make Enough Product (Ad) A tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel.
They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December! Get the name of the company and their stock ticker here >>> |
TNDM Tandem Diabetes Care | $42.83
-0.4% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
SWAV Shockwave Medical | $334.75
| 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $62.00
-0.1% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
PODD Insulet | $196.40
-1.0% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
INSP Inspire Medical Systems | $162.59
-0.7% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
EW Edwards Lifesciences | $88.53
+1.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
DXCM DexCom | $116.64
+0.1% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
AXNX Axonics | $67.51
+0.3% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Axonics (NASDAQ:AXNX) on 10/16/2023 |
GILD Gilead Sciences | $63.15
-1.7% | 10/11/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/11/2023 |
AMGN Amgen | $305.99
+0.9% | 10/11/2023 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
ACLX Arcellx | $53.81
+0.1% | 10/12/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Outperform | | Low | View details for Leerink Partnrs rating of Arcellx (NASDAQ:ACLX) on 10/12/2023 |
SPRY ARS Pharmaceuticals | $8.08
-3.9% | 9/21/2023 | Downgraded by | Leerink Partnrs | Analyst R. Ruiz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
TSBX Turnstone Biologics | $2.73
+1.1% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Turnstone Biologics (NASDAQ:TSBX) on 8/15/2023 |
GLTO Galecto | $0.49
-2.0% | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Galecto (NASDAQ:GLTO) on 8/15/2023 |
DSGN Design Therapeutics | $3.54
-7.3% | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $51.94
-1.6% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
RLAY Relay Therapeutics | $7.03
-0.8% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NUVL Nuvalent | $78.10
+1.2% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $37.27
-0.8% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $21.56
-1.0% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $13.78
-1.9% | 8/8/2023 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $19.44
+0.2% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
WVE Wave Life Sciences | $5.71
-4.7% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Market Perform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 8/4/2023 |
BLTE Belite Bio | $49.65
+0.1% | 7/26/2023 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
